| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Chloroprocaine HCl is a a potent, synthetic and local anesthetic used during surgical procedures. At the injection site, chloroprocaine hydrochloride acts by inhibiting sodium influx through binding to specific membrane sodium ion channels in the neuronal cell membranes, restricting sodium permeability, and blocking nerve impulse conduction. This leads to a loss of sensation. Chloroprocaine hydrochloride is short-acting due to rapid hydrolysis by pseudocholinesterase into para-aminobenzoic acid in plasma.
| ln Vivo |
The lethal dose of chloroprocaine hydrochloride in mice is 97 mg/kg for intravenous administration and 950 mg/kg for subcutaneous administration [1].
|
|---|---|
| References | |
| Additional Infomation |
Chloroprocaine hydrochloride is the monohydrochloride salt of chloroprocaine. Used as a local anaesthetic, particularly for oral surgery, it has the advantage over lidocaine of constricting blood vessels, so reducing bleeding. It has a role as a local anaesthetic, a peripheral nervous system drug and a central nervous system depressant. It contains a chloroprocaine.
Chloroprocaine Hydrochloride is a synthetic, aminoester, local, anesthetic agent. At the injection site, chloroprocaine hydrochloride acts by inhibiting sodium influx through binding to specific membrane sodium ion channels in the neuronal cell membranes, restricting sodium permeability, and blocking nerve impulse conduction. This leads to a loss of sensation. Chloroprocaine hydrochloride is short-acting due to rapid hydrolysis by pseudocholinesterase into para-aminobenzoic acid in plasma. See also: Chloroprocaine (has active moiety). Drug Indication Peripheral nerve block (local anaesthesia by perineural injection) Ocular surface anaesthesia Ocular surface anaesthesia Epidural anaesthesia Intrathecal anaesthesia Intrathecal anaesthesia |
| Molecular Formula |
C13H20CL2N2O2
|
|
|---|---|---|
| Molecular Weight |
307.22
|
|
| Exact Mass |
306.09
|
|
| CAS # |
3858-89-7
|
|
| Related CAS # |
Chloroprocaine;133-16-4
|
|
| PubChem CID |
441348
|
|
| Appearance |
White to off-white solid powder
|
|
| Boiling Point |
402.6ºC at 760 mmHg
|
|
| Melting Point |
176ºC
|
|
| LogP |
3.625
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
7
|
|
| Heavy Atom Count |
19
|
|
| Complexity |
259
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
SZKQYDBPUCZLRX-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C13H19ClN2O2.ClH/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14;/h5-6,9H,3-4,7-8,15H2,1-2H3;1H
|
|
| Chemical Name |
2-(diethylamino)ethyl 4-amino-2-chlorobenzoate;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (20.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.25 mg/mL (20.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 6.25 mg/mL (20.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2550 mL | 16.2750 mL | 32.5500 mL | |
| 5 mM | 0.6510 mL | 3.2550 mL | 6.5100 mL | |
| 10 mM | 0.3255 mL | 1.6275 mL | 3.2550 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03918798 | Recruiting | Drug:Chloroprocaine 1% Injectable Solution Drug:Chloroprocaine 2% Injectable Solution |
Hernia, Inguinal Flat Foot |
Sintetica SA | February 14, 2019 | Phase 2 |
| NCT05926258 | Not yet recruiting | Drug:Chloroprocaine 3% eye gel | Local Anesthetic | Sintetica SA | May 10, 2024 | Phase 3 |
| NCT06302257 | Not yet recruiting | Drug:Chlorprocaine Drug:Lidocaine Drug:Lidocaine-chlorprocaine combination |
Labor Pain | Hadassah Medical Organization | March 1, 2024 | Phase 4 |
| NCT06376058 | Recruiting | Drug:Chloroprocaine 1% Injectable Solution | Cesarean Section Local Anesthetic |
Aretaieion University Hospital | January 10, 2024 | Not Applicable |
| NCT05934253 | Recruiting | Drug:Chloroprocaine ophthalmic gel 3% | Antiseptic Anesthesia, Local |
Harrow Inc | July 15, 2023 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA